LENZ Therapeutics Inc (NAS:LENZ)

Q1 2026 LENZ Therapeutics Inc Earnings Call Transcript

May 11, 2026 / 08:30 PM GMT

Release Date Price: $9.99 (-0.70%)

Transcript 10-Q8-K

Key Points

Positve

LENZ Therapeutics Inc (LENZ) reported a 19% increase in paid and filled prescriptions in Q1 2026 compared to Q4, resulting in approximately $1.7 million in net product revenues.
The company has built a growing base of over 10,000 unique prescribing physicians, indicating strong early adoption.
LENZ Therapeutics Inc (LENZ) is seeing promising patient adoption and persistence, with over two-thirds of e-pharmacy volume coming from three-month prescriptions.
The company is transitioning to an FDA-approved, large-scale manufacturing process to improve product quality and user experience.
LENZ Therapeutics Inc (LENZ) is experiencing strong momentum outside the U.S., with recent European and UK submissions and partnerships in key markets like China, Southeast Asia, Canada, and the Middle East.

Negative

New patient adoption is growing but not at the pace LENZ Therapeutics Inc (LENZ) is aiming for, indicating challenges in accelerating market penetration.
The company is facing a gradual pace of new patient starts and routine ECP prescribing, which is slower than expected.
LENZ Therapeutics Inc (LENZ) reported a net loss of $41.5 million in Q1 2026, with a net loss per share of $1.32.
Total SG&A expenses increased by 13% quarter-over-quarter, driven by planned DTC launch investments, contributing to a higher cash burn.
The company has identified key barriers to adoption, including the need for physicians to incorporate the product more naturally into routine exams and improving the patient journey from awareness to purchase.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

LENZ.OQ - Lenz Therapeutics Inc
Q1 2026 LENZ Therapeutics Inc Earnings Call
May 11, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon, ladies and gentlemen, and welcome to the LENS Therapeutics First Quarter 2026 Financial Results Conference Call.

At this time, all participants are in a listen-only mode. Following prepared remarks from management, we will conduct a question-and-answer session, and instructions will follow at that time. As a reminder, this call is being recorded.

At this time, I would like to turn the call over to Dan Shevelard, Chief Financial Officer. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you. Good afternoon, and thank you for

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.